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The Intersection of Addiction 
and Health Law
The cost to society of alcohol, tobacco, and other drug (ATOD) addiction is huge and unrelenting. These costs 
include the health care costs of ATOD- 
related illnesses; the costs of treating abuse 
and dependence; lost productivity of workers 
who abuse ATOD; premature death of ATOD 
users; costs involving the criminal justice 
system and social welfare administration; 
property losses from drug and alcohol-related 
motor vehicle crashes and fires; and the lost 
productivity of the victims of drug and  
alcohol-related crime and individuals im-
prisoned as a consequence of such crime. 
Statistics that quantify and demonstrate these 
costs are plentiful and alarming:
• The Office of National Drug Control 
  Policy reported that in 2002 untreated 
  substance abuse cost society $181  
  billion, $108 billion of which was  
  associated with drug-related crime.1 
• The National Highway Transportation 
  Safety Administration’s 2007 Annual 
  Assessment of Motor Vehicle Traffic 
  Crash Fatalities and Injuries showed 
  that 31.7% of traffic fatalities were 
  alcohol-related.2 
• The National Bureau of Crime 
  Statistics found that 30% of violent 
  crimes involved an offender who had 
  been drinking and two-thirds of victims 
  who suffered violence by an intimate 
  (a current or former spouse, boyfriend, 
  or girlfriend) reported that alcohol had 
  been a factor.3
• In 2004, the CDC found that the total 
  annual public and private health care 
  expenditure caused by smoking was 
  $96 billion, of which $30.9 billion was 
  federal and state government smoking- 
  related Medicaid payments; $27.4  
  billion comprised Medicare expen- 
  ditures; and $9.6 billion accounted for 
  other federal government tobacco- 
  caused health care costs (e.g. through 
  VA health care).4 
• The CDC also estimated that, in 2004, 
  annual health care expenditures solely 
  from secondhand smoke exposure were 
  $4.98 billion.5 
These statistics, particularly the costs to the 
health care system, demonstrate the impor-
tance of studying and understanding the role 
of the law in facilitating appropriate and sus-
tainable solutions to the problem of misuse 
of alcohol, tobacco and other drugs. Several 
faculty members at the University of Mary-
land School of Law are bringing attention to 
legal issues relating to addiction through their 
scholarship and clinical work. In this issue 
of the newsletter, we look at how the law 
has treated addiction and addicts and current 
legal issues in prevention and treatment.
Addiction is a complicated topic to discuss 
because the various substances to which an 
individual can become addicted have differ-
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ent physiological affects; are regulated 
differently; and are subject to vastly 
different cultural attitudes. The most 
obvious regulatory difference between 
the different classes of addictive sub-
stances is that some are legal and some 
are not. Among those that are legal, i.e. 
alcohol, tobacco and prescription drugs, 
alcohol and tobacco are readily available 
to adults whereas prescription drugs are 
more difficult to procure. Moreover, there 
are varying degrees of stigma attached to 
specific addictions. In the case of alcohol, 
moderate consumption is widespread, 
culturally accepted and even thought to be 
healthful in certain circumstances, e.g., the 
promotion of red wine as a heart-healthy 
beverage. On the other hand, illegal drug 
use is widely reviled and the subject of 
great demonization by politicians and the 
media. Given the differences associated 
with various addictive substances, the 
regulatory and treatment strategies for 
each are quite different. Nonetheless, as 
a deeper understanding of the process of 
addiction has grown over the years, many 
experts group alcohol, tobacco and other 
drug addictions together in order to high-
light the commonalities of these various 
addictions and even the relationship of one 
addiction to another.6 
The first legal measures against drug 
abuse in the United States were aimed at 
opium use. These early measures did not 
target addicts or criminalize their behavior 
but rather were aimed at drug suppliers. 
In a recent article, Law & Health Care 
Program (L&HCP) Director Diane Hoff-
mann describes the history of drug control 
policy in the United States and notes that 
it was not until 1914, with the passage of 
the Harrison Narcotic Act,7 that federal 
law addressed the issue of the non-medical 
use of narcotics.8 The Act forbade the sale 
of substantial doses of opiates or cocaine 
except by licensed doctors and pharma-
cies. The Act effectively criminalized non- 
medically authorized possession of opiates 
and cocaine—the first time criminal sanc-
tions were applied to what had previously 
been considered a purely medical matter.9 
Although the Act permitted the sale 
of opiates for medical use, Federal drug 
agents opposed any form of narcotics 
distribution and harassed physicians who 
pursued narcotic treatment efforts. Many 
physicians argued, however, that treating 
the “agonies of unrelieved addiction” was 
within their duties under the Hippocratic 
Oath.10 Several Supreme Court opinions 
addressed the question of whether the 
Act allowed treatment or maintenance 
of addicts by physicians. Over a six-year 
period starting in 1916, the Court went 
from viewing the Act as allowing physi-
cians to prescribe to addicts to stating 
that prescribing to an addict to keep him 
comfortable by maintaining his customary 
use was not in the course of professional 
treatment, to adopting a view that profes-
sional practice did not include medication 
for the purpose of curing an addict.11 This 
final determination set the stage for practi-
tioner investigations and prosecutions for 
years to come.
Over time, the approach taken by the 
Harrison Act—considering drug use a 
medical issue and limiting federal in-
volvement in regulating drug use —was 
abandoned in favor of the current model 
which treats drug use as a punishable 
behavior and involves vast government 
oversight and regulation of drugs. Arnold 
Trebach, who has written extensively on 
U.S. drug policy, attributes this shift to the 
reluctance on the part of American doc-
tors to fight for the right to make private 
medical judgments, as did their British 
counterparts.12 Until recently, doctors in 
Britain could administer drugs (including 
morphine) to addicts, wean addicts with 
gradually diminishing doses of heroin, or 
maintain them on stable doses of inex-
pensive, pure heroin for the rest of their 
lives. The British approach has, at least 
until recent years, held addiction levels 
stable and largely removed the impetus 
for heroin-related crime. Instead, Trebach 
argues, most American doctors supported 
the efforts of Treasury officials who gradu-
ally regulated away most of the discretion 
the medical community had regarding 
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the use of narcotics. Others have argued 
that the Depression and WWII changed 
the way Americans viewed the role of 
government and this paved the way for the 
federal government to play a more active 
role in drug regulation. 
In 1938, the Food, Drug and Cosmetic 
Act13 was passed to give the government 
a greater role in oversight over the sale 
of drugs and, in 1962, on the heels of the 
thalidomide crisis, the Food and Drug 
Administration (FDA) was established. 
In 1965, amphetamines, barbiturates, 
and, three years later, LSD, were labeled 
as “dangerous drugs” and their use was 
completely banned by the Drug Abuse 
Control Amendments14—the first time the 
federal government completely banned the 
use of a drug, even by prescription from a 
physician. 
In 1969, President Richard Nixon asked 
the Attorney General to prepare a compre-
hensive new measure to combat drug use 
and addiction at the federal level. In addi-
tion, Nixon established the National Com-
mission on Marijuana and Drug Abuse 
to study marijuana abuse in the United 
States. The Commission recommended the 
decriminalization of marijuana in small 
amounts, noting that “[t]he criminal law is 
too harsh a tool to apply to personal pos-
session even in the effort to discourage  
use . . .. The actual and potential harm 
of use of the drug is not great enough to 
justify intrusion by the criminal law into 
private behavior, a step which our soci-
ety takes only ‘with the greatest reluc-
tance.’”15 
The recommendations of the Com-
mission were not followed and shortly 
thereafter, in 1970, Congress passed the 
Controlled Substances Act (CSA) which 
created the Drug Enforcement Agency.16 
The CSA classifies controlled substances 
into one of five schedules based on their 
potential for abuse, psychological or 
physiological dependence, and medical 
uses. Drugs in each Schedule are sub-
ject to different rules for prescribing and 
distribution. The CSA also creates a closed 
system of distribution for those autho-
rized to handle controlled substances. The 
cornerstone of this system is the registra-
tion of all those authorized by the DEA to 
handle controlled substances. 
It is widely acknowledged that the CSA 
brought about the nation’s current ap-
proach to the problem of substance abuse. 
Instead of adhering to the medical model 
represented by the Harrison Act, the CSA 
placed drug use squarely in the individual 
behavioral realm with the government 
playing the role of enforcer.17 
The CSA marked the beginning of what 
President Nixon called the “war on drugs.” 
In addition to federal control of substances 
considered drugs, the campaign has also 
included efforts on the part of the govern-
ment, with the assistance of participating 
countries, to reduce the illegal interna-
tional drug trade by curbing the produc-
tion and distribution of drugs. Critics have 
noted that, for all the damage the cam-
paign has done to our relations with drug-
producing countries and on a generation of 
young black men who were incarcerated 
on drug charges, the drug war has likely 
been ineffective in stemming illegal drug 
use or addiction. In 2001, the National 
Research Council’s Committee on Data 
and Research for Policy on Illegal Drugs 
published its findings on the efficacy of 
the drug war.18 The Committee found that 
existing studies on the effectiveness of 
efforts to eliminate illegal drug use and 
smuggling have all been inconclusive. 
While the government has criminal-
ized possession and use of controlled 
substances without a doctor’s prescription, 
since the country’s failed attempt at pro-
hibition of alcohol in the 1920s and early 
30s, alcohol has primarily been regulated 
through minimum drinking ages and warn-
ing labels. The federal Alcoholic Beverage 
Labeling Act, enacted in 1988, requires 
the labels of alcoholic beverages to carry a 
warning notice and, following the pas-
sage of the National Minimum Drinking 
Age Act of 1984, all 50 states adopted a 
minimum drinking age of 21 in order to 
ensure a continued flow of federal trans-
portation dollars. On the state level, after 
prohibition, most states created either state 
agencies to issue licenses for retail liquor 
sales, state monopolies on liquor sales, or 
hybrid blends of the two systems. Within 
the federal framework noted above, state 
and county liquor agencies exercise a 
broad range of powers over the conditions 
under which alcohol is advertised, sold, 
and consumed. 
Similar to alcohol, tobacco is also 
regulated primarily through age-related 
purchasing restrictions and warning labels. 
There have been many unsuccessful at-
tempts to bring tobacco under the con-
trol of the FDA, mostly recently via the 
Family Smoking Prevention and Tobacco 
Regulation Act that passed the House last 
summer but faced a veto threat from then-
President George W. Bush and did not get 
a vote in the Senate. Rep. Henry Waxman 
recently reintroduced the bill. Cur-
rently the federal government minimally 
regulates tobacco via Surgeon General 
warnings, prohibition of television adver-
tising, certain tar and nicotine disclosures, 
regulation of cross-border smuggling, and 
some agricultural safeguards. The federal 
government also requires states to meet 
certain targets for reductions in youth 
access to tobacco but the setting of an age 
restriction is purely a state issue. States 
and municipalities also regulate tobacco 
through a variety of rules relating to where 
and when tobacco products can be pur-
chased and consumed. 
Addiction continues to be a pervasive 
problem in the United States. Epidemio-
logical data suggest that lifetime preva-
lence rates for substance abuse disorders 
among adults in the United States are 
13.5% for alcohol dependence and abuse19 
and 6.1% for other drug dependence and 
abuse.20 Rates of addiction are even higher 
among vulnerable populations such as 
the institutionalized, the incarcerated and 
the homeless. Drug addiction is one of 
the most common diseases in the United 
States. It is estimated that over nine 
million Americans need drug treatment, 
making addiction more prevalent than 
coronary heart disease and stroke and as 
prevalent as cancer.
Virginia Rowthorn, JD 
Managing Director, L&HCP
1 The Economic Costs of Drug Abuse in 
the United States: 1992–2002, Office of 
National Drug Control Policy, available at 
http://www.whitehousedrugpolicy.gov/publi-
cations/economic_costs/further.pdf.
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about the nation’s current approach to the problem of substance abuse. In-
stead of adhering to the medical model represented by the Harrison Act, the 
CSA placed drug use squarely in the individual behavioral realm with the 
government playing the role of enforcer.
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Maryland Faculty Use Law to Reduce  
Addiction and Improve Treatment
Many scholars and advocacy orga-nizations argue that the greatest failure of current drug policy 
has been the emphasis that it places on in-
vestigation, prosecution and incarceration 
of drug possession offenders, rather than 
funding, and improving access to, drug 
screening and treatment. This is also true 
in the area of alcohol abuse—with more 
resources going toward punishment of 
drunk drivers and perpetrators of domestic 
violence than toward screening and treat-
ment. Inadequate screening for addiction 
and limited access to quality treatment are 
widely considered the greatest obstacles 
to addressing the issue of addiction in the 
United States. In addition to underfund-
ing and limited capacity, other problems 
inhibit effective treatment including lack 
of availability of a wide range of effective 
treatment modalities, lack of insurance 
coverage for drug and alcohol treatment, 
and, in the specific case of drug treat-
ment, the NIMBY (Not in My Backyard) 
problem that can block the opening of 
treatment facilities in a community. Law 
& Health Care Program faculty have been 
working on finding innovative solutions 
to some of the more intractable problems 
of ATOD misuse through their scholar-
ship and the law school’s Drug Policy and 
Tobacco Control Clinics. Some of those 
efforts are described below.
SCreening
Experts in the area of addiction are 
urging health care providers to become 
involved much earlier to help iden-
tify alcohol and drug problems in their 
patients. Alcohol and other drug testing 
and screening can be a useful clinical 
and public health tool when it can help 
identify people with alcohol or other drug 
problems not otherwise identified as need-
ing clinical intervention. Currently, most 
screening takes place on the job, in the 
schools, and in the criminal justice system, 
and is used as an instrument of harassment 
and punishment rather than a diagnostic 
tool.
One context in which testing is not 
being sufficiently used is in medical set-
tings, especially in trauma centers and 
emergency rooms. Studies repeatedly 
show that 40-50% of patients who show 
up in trauma centers were drinking alcohol 
at the time of their injuries.1 Most of 
these patients are chronic heavy drink-
ers. The evidence also clearly shows that 
a brief motivational intervention at such 
a “teachable moment” reduces alcohol 
consumption and the associated risk of 
injury. Experts argue that blood alcohol 
testing should be routinely conducted for 
patients admitted to emergency rooms for 
traumatic injuries, and that all legal, proce-
dural, and financial barriers to such testing 
should be removed. 
University of Maryland School of Law 
Professor Richard Boldt has written about 
emergency room screening. In his most 
recent article, “Confidentiality of Alcohol 
and Other Drug Abuse Treatment Informa-
tion for Hospitalized Trauma Patients,”2 
Boldt discusses the obstacles to integration 
of alcohol and other drug abuse treat-
ment services into the health care delivery 
system. He notes that, despite encourag-
ing statistics and broad support among 
trauma surgeons and other emergency 
medical personnel, many trauma centers 
and emergency departments still do not 
provide systematic screening and interven-
tion services for all patients. He believes 
that providers’ concerns about federal 
confidentiality statutes and regulations 
governing alcohol and other drug abuse 
treatment information may be inhibiting 
their willingness to engage in system-
atic screening, intervention, and referral 
activities. Boldt suggests that the federal 
confidentiality law and regulations may 
not apply to these kinds of screening and 
intervention activities and cautions against 
any change in current law that might result 
in inappropriate disclosure of this patient 
information.
Professor Ellen Weber, Director of the 
Law School’s Drug Policy and Public 
Health Strategies Clinic, has investigated 
the screening of pregnant women for 
drug use in her scholarship and in clinic 
projects. In her article, “Child Welfare 
Interventions for Drug-Dependent  
Pregnant Women: Limitations of a Non-
Public Health Approach,”3 Weber explored 
the merits of early medical screening of 
pregnant women for alcohol and drug 
use rather than punitive interventions 
that occur at the time of delivery. More 
recently, Weber has examined the common 
hospital practice of conducting drug tests 
of women at delivery without obtaining 
informed consent. Such testing often tar-
gets women who have participated in drug 
treatment and poor women of color who 
have not had adequate prenatal care. The 
failure to obtain informed consent raises 
concerns, according to Weber, because 
these drug tests are the basis for child 
protective services reports in many states, 
including Maryland, and may result in the 
removal of the infant from the mother’s 
custody. Weber is exploring the ethical and 
legal basis for requiring informed consent 
in this context.
 In her clinic work, Weber and her 
students have represented the Maryland 
Women’s Treatment Coalition in its 
challenge of the Department of Human 
Resources policy that requires hospitals to 
report women and infants who have posi-
tive drug tests to child protective services. 
The focus of their challenge is twofold: 
the agency has not adopted the policy via 
the regulatory process required under the 
Maryland Administrative Procedure Act 
(APA) and the substantive standards are 
inconsistent with the state’s child abuse 
and neglect standard. After two years of 
negotiation with the state agency to cor-
rect the policy, the clinic has petitioned the 
agency to promulgate the regulations and 
is seeking an Attorney General opinion 
regarding the need for promulgation of 
the regulation. The clinic is seeking to halt 
the implementation of the policy pending 
compliance with the APA.    
Professor Richard Boldt
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ACCeSS to Drug treAtment
The 2001 National Household Survey 
on Drug Abuse found that five million 
people who needed treatment did not get 
it and treatment professionals estimate 
that only one in ten people receive the 
treatment they need.4 Among the reasons 
for this failure are inadequate insurance 
coverage and a lack of sufficient treatment 
facilities and options. 
Insurance Coverage
Drug treatment—whether paid for by 
health insurance or provided by a govern-
ment entity—is underfunded and difficult 
to access. More than 70% of people who 
currently use illicit drugs, as well as 75% 
of individuals who are alcoholics, are 
employed and most are covered by health 
insurance.5 However, an ongoing concern 
has been the historic failure on the part of 
health insurance plans to provide the same 
coverage for drug and alcohol treatment as 
they do for the treatment of other medical 
conditions. The first step toward greater 
insurance coverage of diagnosis and treat-
ment were mental health parity laws that 
required health insurers to cover mental 
health conditions to the same extent physi-
cal conditions were covered. However, 
mental health parity laws did not result in 
coverage of addiction treatment services 
as hoped despite the fact that studies found 
that covering such services does not con-
tribute to healthcare cost increases.6 
In 1994, Maryland and two other states 
led the charge in this area by enacting 
comprehensive mental health parity laws 
for all state residents.7 The Maryland law 
requires non-discriminatory coverage for 
any person with a mental illness, emotion-
al disorder, drug abuse, and alcohol abuse. 
The law also provides that, if a company 
with 50 or more employees provides for 
inpatient coverage for mental health and 
substance abuse treatment, those condi-
tions must be covered in the same way that 
physical illnesses are covered. In 2007, 
Congress finally passed the Paul Wellstone 
and Pete Domenici Mental Health Parity 
and Addiction Equity Act of 2008.8 The 
Act does not require health insurance 
plans to cover addiction or mental health, 
but insurers will now be barred from 
imposing any caps or limits on behavioral 
healthcare services that are not applied to 
other health conditions if such coverage is 
offered. 
For uninsured, drug dependent individu-
als, drug treatment options are also very 
limited. Although research demonstrates 
that sound treatment practices and policies 
save lives, reduce crime, rebuild families 
and communities, and use public funds 
wisely, there remains a vast unmet need 
for treatment. Inadequate funding has led 
to a longstanding shortage of publicly 
funded treatment.
Professor Weber and her students in the 
Drug Policy and Public Health Strate-
gies Clinic have used legal and other 
advocacy techniques to both force and 
encourage Baltimore City and the state 
of Maryland to provide better services. In 
recent years, Weber has worked with the 
National Council on Alcoholism and Drug 
Dependence (NCADD) of Maryland on its 
Medicaid reform initiative. The Maryland 
Department of Health and Mental Hygiene 
(DHMH) was using a comprehensive 
protocol—the Substance Abuse Improve-
ment Initiative—to ensure easier access 
to services and more reliable treatment 
authorization and reimbursement prac-
tices but the protocol has been plagued by 
adherence problems because the stan-
dards are not contained in regulations and 
enforcement has been weak. NCADD, 
Weber, and clinic students held meetings 
with providers and DHMH staff to obtain 
their feedback on the protocol, then devel-
oped recommendations for improving the 
protocol and addressing other issues that 
have hampered the delivery of services un-
der Medicaid. The clinic also worked with 
NCADD to spearhead a legislative effort 
to study Medicaid managed care policies 
relating to the treatment of addiction. The 
bill was pulled from consideration by the 
Maryland General Assembly, but DHMH 
Secretary John Colmers created a Medic-
aid Substance Abuse Workgroup to study 
the issue. The clinic participated in the 
Workgroup during the summer and fall of 
2008 and proposed a number of recom-
mendations to address administrative 
barriers to accessing addiction treatment 
services. Among the recommendations 
that DHMH has agreed to are adoption of 
the Substance Abuse Improvement Initia-
tive in regulation and improved documen-
tation of denials of care. Clinic students 
developed the draft regulation and have 
presented it to DHMH.  
NIMBY Phenomenon
The NIMBY—Not In My Back Yard—
phenomenon is another formidable barrier 
to adequate community-based drug treat-
ment. Many individuals who support drug 
treatment do so as long as it is not located 
in their community. Although health and 
safety considerations are understandable, 
they are most often based on misun-
derstanding and a false sense that drug 
treatment creates crime and instability in a 
community. Professor Weber, through the 
Drug Policy Clinic, has been involved in 
several efforts to oppose NIMBY attitudes 
and policies. In collaboration with the 
Citizens Planning and Housing Asso-
ciation (CPHA), Weber and her students 
participated in drafting a consensus docu-
ment called “Common Ground–Not Battle 
Ground: Good Neighbor Principles for Li-
censed Drug Treatment Providers and the 
Communities Where They Are Located.” 
Completed in 2004, this landmark docu-
ment articulates, perhaps for the first time 
in the nation, a set of principles that can 
guide communities and treatment provid-
ers to identify treatment opportunities and 
resources for community residents, and 
where residents support those in recovery.
Weber and her students also successful-
ly persuaded the Department of Justice to 
open an investigation of the Drug Policy 
Clinic’s complaint that Baltimore City’s 
zoning standards for residential drug 
treatment discriminate against individu-
als with histories of drug dependence. 
Weber and her students filed an extensive 
Title II (Americans with Disabilities Act) 
complaint in May 2006 with the Disabil-
ity Rights Section of DOJ. In May 2007, 
the Assistant Attorney General for Civil 
Rights approved the investigation and 
then determined that the City’s standard 
violated the ADA. The Mayor of Balti-
more introduced legislation to address the 
problem in December 2007 after months 
of negotiation between the City, the DOJ, 
and the Drug Policy Clinic on the appro-
priate standards. In the past year, the clinic 
Professor Ellen Weber (left)
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has participated in City Council hearings, 
work sessions and education efforts but 
has been unable to win passage of the bill 
by the City Council. In December 2008, 
the DOJ informed the City that it will 
file suit if it fails to remedy to problem 
promptly.  
treAtment-reLAteD iSSueS
Drug Courts
In the absence of publicly funded 
treatment programs, increasingly, people 
without financial means are only provided 
with drug treatment through the criminal 
justice system. After being arrested for 
drug related crimes, many states, in-
cluding Maryland, divert offenders into 
treatment. This often happens through 
specialized courts commonly referred to 
as drug courts. Over 2,000 drug courts are 
currently in place or being planned across 
the United States. These special dockets 
are given the responsibility to handle 
cases involving addicted citizens under the 
adult, juvenile, family, and tribal justice 
systems. Adult drug courts started out as 
diversionary programs dealing with less-
serious offenders, typically those charged 
with simple drug possession or “under the 
influence” charges. Over time, drug court 
programs have expanded to probationers, 
including drug-using offenders charged 
with non-drug offenses. Typically, only 
non-violent offenders are eligible for adult 
drug court. 
Although many agree that individuals 
addicted to drugs should be treated for 
their illnesses rather than incarcerated as 
criminals, there is a disagreement over the 
value of drug courts and other “problem-
solving” courts as a way to deal with these 
individuals.9 Many experts see them as a 
cost-effective and humane alternative to 
incarceration while others worry that drug 
courts and other diversion programs are 
available only to a small percentage of 
eligible and needy individuals, and these 
models problematically rely heavily on 
non-therapeutic drug testing and coercion. 
This debate is thriving among faculty at 
the Law School. 
Professor Brenda Bratton Blom, Direc-
tor of the Law School’s Clinical Law 
Program, and her students in the Com-
munity Justice Clinic recently drafted an 
amicus brief in support of the Maryland 
Attorney General, appellee in Brown v. 
State of Maryland, which is due to be 
heard by the Maryland Court of Ap-
peals in its April term. The case, brought 
by the Office of the Public Defender in 
Maryland, questions the constitutional 
and statutory validity of problem-solving 
dockets in Maryland’s state courts. The 
amicus brief highlights the constitutional, 
statutory, and administrative mandates 
that grant Maryland courts the power to 
conduct specialized dockets, such as drug 
and mental health courts. The brief also 
refutes assertions that these dockets allow 
judges to overstep the bounds of their 
neutral magistracy and enables them to 
engage in “social engineering” in violation 
of defendants’ due-process rights. 
Professor Richard Boldt has recently 
written a book chapter entitled, “A 
Circumspect Look at Problem-Solving 
Courts,”10 that questions the “uneasy 
partnership” of the criminal justice system 
and drug treatment. In his chapter, and in 
several other articles he has published on 
this subject, Boldt explores the disadvan-
tages as well as the advantages of combin-
ing therapy with legal coercion in such 
courts, given the roles assumed by judges, 
defense lawyers, and other actors in that 
setting. One of Boldt’s primary concerns 
is that the therapeutic goals identified 
by these courts often become debased 
in practice. This tendency of therapeutic 
efforts located within the criminal jus-
tice system to collapse into more purely 
punitive responses is especially troubling 
to Boldt because they often take place 
in settings where traditional procedural 
protections are weakened or abandoned. 
Boldt concludes that it may be appropri-
ate to use problem-solving courts in more 
limited applications than those currently in 
practice. 
Treating Addiction with  
  Pharmacotherapies
Historically, drug and alcohol addic-
tions were considered acute disorders best 
treated through detoxification and other 
short-term strategies. In recent years, there 
has been a growing understanding of ad-
diction as a chronic disease that requires 
long-term relapse prevention therapy. At 
the same time that our understanding of 
addiction as a chronic disease has devel-
oped, so has the ability to treat patients 
with pharmacotherapies. While there is 
a growing body of evidence that the use 
of pharmacotherapies to treat drug and 
alcohol addictions is both clinically and 
cost effective, there are still a number 
of obstacles that exist to their develop-
ment and use in the therapeutic setting. In 
November 2008, the Law & Health Care 
Program, in collaboration with Physicians 
and Lawyers for National Drug Policy 
(PLNDP), held a conference that explored 
the various impediments that stand in 
the way of a more robust acceptance of 
such treatment by regulators, health care 
providers, patients, and the justice system 
(See article, p. 9 on conference keynote 
lecture given by Professor Richard Bon-
nie). 
Panelists at the conference described 
the obstacles that exist at each stage of 
drug development and uptake, including 
obstacles at the pharmaceutical company 
level; obstacles relating to clinical trials 
and the FDA approval process; reluctance 
of patients to use and providers to screen 
for, and prescribe, medications to treat 
addiction; and reluctance on the part of 
insurance companies to adequately reim-
burse for their use. In addition, because 
as mentioned above, an important number 
of individuals receive treatment for their 
addictions through the criminal justice 
system, one of the conference panels was 
devoted to discussion of the reluctance 
of drug court judges to employ pharma-
cotherapies. The panel included two drug 
court judges and a leading sociologist who 
has studied the use of such treatment in 
the courts. Another panel took a look at 
recent efforts to use cutting edge treat-
ments elsewhere in the criminal justice 
system and in prisons (A video of the 
conference is available at http://www.law.
umaryland.edu/faculty/conferences/detail.
html?conf=71).
One of the newest medications being 
used to treat addiction is buprenorphine, 
a semi-synthetic opiate that can be used 
Professor Brenda Bratton Blom
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in the management of opioid dependence 
(that is, dependence on heroin, oxycodone, 
hydrocodone, morphine, oxymorphone 
and other opioids). The Suboxone and 
Subutex preparations of buprenorphine 
were approved for this indication by the 
FDA in October 2002. The FDA’s approv-
al was facilitated by the Drug Addiction 
Treatment Act of 2000 that, for the first 
time since 1914, made it legal for doctors 
to prescribe opioids to manage addiction 
in an office-based practice. Prior to the 
passage of the Act, the only medication-
based treatment option available to opiate 
addicts was to obtain methadone treatment 
at federally-approved outpatient clinics.
 The use of medication-assisted treat-
ment in the management of opioid depen-
dence is controversial and highly regu-
lated, owing to the fact that the premise 
of such treatment is treating an addiction 
with a medication rather than relying on 
the abstinence based model that is central 
to Alcoholics Anonymous and Narcotics 
Anonymous. A special federal waiver is 
required to prescribe Subutex and Subox-
one for opioid addiction treatment on an 
outpatient basis. Each approved prescriber 
is allowed to manage only thirty patients 
on buprenorphine for opioid addiction as 
outpatients during his or her first year of 
treating patients, although Congress has 
passed a bill relaxing this restriction for 
group practices. 
Buprenorphine has several advantages 
over methadone treatment. For example, 
it is generally viewed to have a lower “de-
pendence-liability” than methadone, i.e., 
withdrawal from buprenorphine is less dif-
ficult. Additionally, the opinion of those in 
the medication-assisted treatment field is 
generally shifting to longer-term treatment 
periods (which may last indefinitely) due 
to the anti-depressant effects Buprenor-
phine seems to have on some patients, as 
well as the high relapse potential among 
those patients discontinuing methadone 
maintenance therapy. Patients generally 
prefer buprenorphine over methadone due 
to the less restrictive outpatient treat-
ment; the less frequent need to go to the 
clinic for prescriptions; and the reduced 
“stigma” of going to a doctor’s office as 
compared to making trips to a methadone 
clinic. 
Tobacco
While we often think of drugs and alco-
hol when we think of addiction, tobacco 
is another powerful addictive substance. 
In 1988, Surgeon General C. Everett 
Koop in a 618-page report proclaimed that 
“cigarettes and other forms of tobacco are 
addicting” and should be treated with the 
same caution as illegal street narcotics.11 
The report caused doctors, smokers and 
public health experts and advocates to 
view tobacco differently—not as a matter 
of choice, but a matter of addiction. 
In the years since, additional research 
has been done on the addictive proper-
ties of tobacco and the resulting difficulty 
tobacco users face when they try to quit. 
According to the National Institute on 
Drug Abuse, of the approximately 70.3 
million Americans who use tobacco prod-
ucts annually, nearly 35 million of them 
want to quit each year but only about six 
percent of people who try to quit are suc-
cessful for more than a month.12 Research 
has shown that nicotine acts on the brain 
to produce a number of effects, primarily 
by increasing the level of dopamine in the 
brain’s “reward” circuits. The resulting 
pleasurable sensations create a physiologi-
cal demand for additional nicotine that is 
both physically and psychologically hard 
to withstand—hence the creation of an 
addiction. If tobacco users attempt to stop 
using tobacco, they suffer from nicotine 
withdrawal—the symptoms of which 
include irritability, craving, cognitive and 
attentional deficits, sleep disturbances, and 
increased appetite. These symptoms often 
begin within a few hours after the last 
cigarette, quickly driving people back to 
tobacco use. 
As we reported in our Spring 2007 issue 
of the newsletter, the law school’s Legal 
Resource Center for Tobacco Regulation, 
Litigation and Advocacy (the “Center”) 
provides legal resources for community 
groups, state and local legislatures and 
agencies, private entities, and lawyers at-
tempting to reduce smoking and its related 
health impacts in communities and assist 
local organizations take a leadership role 
in developing strategies and advocating 
for local legislation. In 2005, the Cen-
ter advocated for insurance coverage of 
medication for the treatment of tobacco 
cessation. Although only covering pre-
scription cessation treatment drugs and not 
over-the-counter drugs like the gum and 
patch, Maryland Insurance Code section 
15-841 now requires that insurers cover 
tobacco cessation prescription medications 
if prescription coverage is provided for in 
the insurance contract. Therefore, since 
2005, most insured Marylanders have had 
access to prescription tobacco cessation 
medications.13 
At the current time, Center Director 
Kathleen Dachille and her students are 
working with members of the Maryland 
General Assembly in support of the fol-
lowing measures:
• Cigar Packaging Requirement: a law 
   that would require a minimum pack 
   of four, so that cigars cannot be sold 
   as singles, which are attractive to 
   minors. If enacted, Maryland would  
   be the first state to have such a law.
• Smoking in Cars with Children: a 
    law that would prohibit smoking 
    in cars with children eight years  
    of age or younger. 
• Civil Citations for Sales to Minors: 
    a law that would enhance local  
    governments’ power to fine retailers 
    who sell tobacco to minors.
The Center also recently launched a 
website to assist tenants and landlords 
dealing with secondhand smoke drift in 
the multiunit housing setting. The web-
site, www.mdsmokefreeapartments.org, 
provides tenants information about their 
legal rights and how they can be involved 
to stop the smoke drift problem.
The use of tobacco, and the related ad-
diction and illness that accompany its use, 
is persistent. Comprehensive and dynamic 
public health strategies are necessary to 
prevent initiation and aid in cessation. As 
rates of tobacco use remain stagnant, this 
help is essential to the public health com-
munity.
1 Screening, Brief Intervention, Referral, 
and Treatment of Acute Care Patients for 
Alcohol Use Disorders, A Position Paper 
from Physicians and Lawyers for National 
Drug Policy, available at http://www.
Cont. on page 11
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Dean Karen Rothenberg  
To Step Down in June
Karen Rothenberg announced last spring that she will step down from her position as Dean of the 
University of Maryland School of Law on 
June 30, 2009. After a sabbatical, Rothen-
berg plans to return to the faculty. Rothen-
berg came to the law school in 1983 and, 
with Associate Dean Diane Hoffmann who 
arrived in 1987, created the Law & Health 
Care Program with Rothenberg serving as 
its first Director. While she will be greatly 
missed in her role as Dean, her return to 
being a full-time member of the Law & 
Health Care Program faculty will be a 
boon to the Program’s students and the 
faculty alike. 
Although she won’t be busy with law 
school business anymore, Rothenberg 
shows no sign of slowing down. She will 
serve as Co-Chair of the World Stem Cell 
Summit that is taking place in Baltimore 
this September. The summit will be a 
gathering of more than 1,500 stem cell 
scientists, physicians, and researchers 
from the United States and around the 
world. Sponsored by the Genetics Policy 
Institute, the 2009 Summit is hosted by the 
University of Maryland, Johns Hopkins 
University, Maryland Department of 
Business and Economic Development, 
Maryland Technology Development 
Corporation, and the Maryland Stem Cell 
Commission. Rothenberg has served on 
the Maryland Stem Cell Commission 
since its inception in 2006 and is currently 
serving as its Chair. 
This summit will be the fifth such sum-
mit and promises to be particularly inter-
esting with the recent renewal of federal 
funding for embryonic stem cell research. 
The summit will focus on both scientific 
and non-scientific aspects of stem cell 
research including progressive research 
strategies, translational and preclinical 
findings, cross disciplinary initiatives, 
drug discovery, funding opportunities 
(federal, public, and private), commercial-
ization plans, technology transfer plat-
forms, medical tourism challenges, cell 
banking projects, insurance questions, and 
international perspectives.
Addiction and Health Law
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– Alcohol-Impaired Driving Fatalities, 
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5 Id.
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“gateway” drugs that open the door for later 
use of more serious drugs. 
7 Harrison Narcotic Act, ch. 1, 38 Stat. 785 
(1914).
8 Hoffmann, D., “Treating Pain v. Reducing 
Drug Diversion and Abuse: Recalibrating 
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Policies,” St. Louis Journal of Health Law & 
Policy, Vol. 1 Issue 2, p. 231.
9 Hoffmann, supra note 8, quoting from 
Weissman, J., Drug abuse: tHe Law aND 
treatmeNt aLterNatives 117 (1978).
10 Hoffmann, supra note 8, quoting King, R., 
“The Narcotics Bureau and the Harrison Act: 
Jailing the Healers and the Sick,” 62 Yale 
L.J. 736, 739 (1953).
11 See United States v. Jin Fuey Moy, 241 
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U.S. 86 (1919), United States v. Behrman, 
258 U.S. 280 (1922).
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sity Press, 1982. 
13 § 1, 21 U.S.C. § 321(g)(1) (1988).
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15 The Report of the National Commission 
on Marihuana and Drug Abuse, available at 
http://www.druglibrary.org/schaffer/Library/
studies/nc/ncmenu.htm.
16 Comprehensive Drug Abuse Prevention 
and Control Act of 1970, Pub. L. No. 91-
513, § 100, 80 Stat. 1236, 1242 (1970).
17 See, e.g., Galiber, J. “A Symposium on 
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Criminal Drug Laws: Replacing Prohibition 
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L. and Med. 207 (1986).
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emies Press, 2001.
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The STuArT roMe  
LeCTure 
The Rome Lecture was established in 
January 1984 to honor the memory of 
Stuart Rome, a prominent attorney, 
community activist, and art patron in 
the Baltimore area who died in 1983.  
Past Rome lecturers have included 
Larry Gostin (Georgetown Univer-
sity), Robert Burt (Yale University), 
Alta Charo (University of Wisconsin), 
Nancy-Ann DeParle (former Director 
of CMS), Paul Steven Miller (Uni-
versity of Washington), William Sage 
(University of Texas) and Sara Rosen-
baum (George Washington Univer-
sity).
Stuart Rome Lecturer Richard Bonnie Speaks 
at L&CHP Conference on Addiction
Professor Richard Bonnie, an expert in the fields of mental health and drug law, was this year’s Stuart 
Rome Lecturer. Bonnie’s lecture was 
the keynote speech at the Law & Health 
Care Program’s November conference 
“Obstacles to the Development and Use 
of Pharmacotherapies for Addiction.” His 
talk, “The Virtues of Pragmatism in Drug 
Policy,” will be published in an upcoming 
issue of the law school’s Journal of Health 
Care Law & Policy.
Professor Bonnie, who has been 
involved in the development of national 
drug policy for over 30 years, spoke 
about the need to adopt evidence-based 
strategies to address drug addiction and 
move away from the current ideological 
approach that for years has paralyzed the 
nation’s efforts to properly address the 
problem of addiction. According to Bon-
nie, in the late 60s and early 70s, policy 
makers embraced a reformist approach 
toward addiction that emphasized the need 
to treat addicts therapeutically rather than 
criminally. However, exploding drug use 
in the early 70s alarmed policy makers and 
led to the initiation of the “War on Drugs” 
and a zero tolerance approach that rejected 
reformist views. Bonnie believes that 
the pendulum is finally swinging away 
from this approach because it has become 
increasingly clear that the War on Drugs 
has caused a great deal of damage at great 
cost, with little evidence that it has made 
any impact on drug use or addiction. 
Going forward, Bonnie suggests that 
drug policy makers adopt three goals 
—learn how to use the vocabulary of ad-
diction to describe the disease accurately; 
create incentives and opportunities for ad-
dicts to seek treatment voluntarily; and en-
courage and fund appropriate non-coercive 
therapeutic treatment of addiction through 
the criminal justice system. Bonnie argued 
that experts in the area of addiction need 
to learn how to speak about addiction in a 
way that includes the concepts of disease 
and choice. The current catch phrase of 
the addiction movement—“addiction is a 
brain disease”—is accurate but does not 
capture the volitional components of ad-
diction and relapse. The phrase therefore 
diminishes a robust understanding and 
acceptance of the complexity of addiction 
and how to address it. Bonnie suggests 
using the concepts of compulsion, predis-
position, and an impairment of volition to 
better explain addiction. He asserts that 
the concepts of disease and choice can be 
compatible if explained correctly.
Bonnie’s second and third points are 
related. He believes that, ideally, drug 
treatment should be widely available to 
any individual who needs it and that such 
treatment should be publicly funded for 
those who cannot afford it otherwise. He 
argues that incentives—even financial 
incentives—should be in place to encour-
age addicts to seek treatment voluntarily. 
The importance of voluntariness is why 
he believes that drug treatment through 
the criminal justice system is so fraught 
with difficulty—such treatment is essen-
tially forced upon an addict and therefore 
subject to all the negative consequences of 
coerced behavior. 
In terms of the criminal justice system, 
Bonnie shared two thoughts with confer-
ence attendees. While he strongly sup-
ports decriminalization of addiction, he 
is skeptical of current efforts (through the 
use of neuroimaging and genetic tests) to 
use addiction as a defense in the criminal 
context. He argues that this goes too far in 
erasing the personal responsibility com-
ponent of addiction that must be acknowl-
edged. Accepting personal responsibility 
for behaviors caused by addiction is what 
addiction therapists teach their clients and 
is at the heart of chronic disease manage-
ment. Bonnie supports the role that the 
criminal justice system plays in addic-
tion – as a deterrent to criminal behavior 
associated with addiction and, more 
importantly, as leverage for therapeutic 
treatment. He believes that this leverage 
should be used not to coerce individuals 
into treatment but to provide them with the 
choice to begin treatment. 
Bonnie is the Harrison Foundation 
Professor of Medicine and Law, Hunton & 
Williams Research Professor, and Profes-
sor of Psychiatry and Neurobehavioral 
Sciences at the University of Virginia. He 
has been Associate Director of the Nation-
al Commission on Marihuana and Drug 
Abuse (1971-73); Secretary of the first 
National Advisory Council on Drug Abuse 
(1975-80); chair of Virginia’s State Human 
Rights Committee responsible for protect-
ing rights of persons with mental disabili-
ties (1979-85), and chief advisor for the 
ABA Criminal Justice Mental Health Stan-
dards Project (1981-88). He is currently 
chairing a Commission on Mental Health 
Law Reform at the request of the Chief 
Justice of Virginia and participating in the 
MacArthur Foundation Research Network 
on Mandated Community Treatment and 
in a new MacArthur Foundation Initiative 
on Neuroscience and Law.
Rome Lecturer Richard Bonnie
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Law & Health Care Faculty  
Staff Legislative Task Force  
on Health Occupation Boards
In Spring 2008, the Maryland Legis-lature passed HB 811, which created the Task Force on Discipline of Health 
Care Professionals and Improved Patient 
Care. The Task Force was created to study 
and issue recommendations relating to 
Maryland’s 18 health occupations boards. 
The legislation directed the Task Force to 
make recommendations regarding board 
discipline, the organizational structure of 
the boards and their relationship to the 
Department of Health and Mental Hygiene 
(DHMH), and to take measures to enhance 
fair, consistent and speedy resolution 
of complaints made against health care 
providers. Composed of representatives of 
the health occupation boards, their execu-
tive directors, the Office of the Attorney 
General (OAG), the DHMH, the Office of 
Administrative Hearings, patient advocacy 
groups, attorneys who represent licensees 
before the boards, and consumers of health 
care services, the Task Force met nine 
times at the Law School from September 
2008 until January 2009 and issued a re-
port with 24 recommendations on January 
31st. Law & Health Care Program Direc-
tor Diane Hoffmann and Managing Direc-
tor Virginia Rowthorn (along with Carl 
Ameringer, Professor of Health Policy and 
Politics at the L. Douglas Wilder School of 
Government and Public Affairs at Virginia 
Commonwealth University) were asked 
to staff the Task Force by Dan O’Brien, 
Principal Counsel at DHMH. 
The origin of the Task Force can be 
traced to allegations that the Maryland 
Board of Dental Examiners abused its dis-
ciplinary authority by disproportionately 
disciplining minority dentists. In 2007, 
Maryland House of Delegates member 
Shirley Nathan-Pulliam introduced a bill 
that called for evaluation of, and sig-
nificant structural changes to the Dental 
Board. The bill hearing included extensive 
testimony from licensed dentists who felt 
that the Board’s sanctioning decisions had 
a differential impact on licensees based 
on race or ethnicity. The bill was vetoed 
for technical reasons but in May 2007, the 
Governor directed the DHMH’s Office of 
the Inspector General (OIG) to audit the 
Dental Board with the goal of determin-
ing whether the disciplinary operations 
and sanctioning outcomes of the Board 
incorporated bias and inequities. The OIG 
report was somewhat inconclusive be-
cause, as it noted, “the Dental Board’s data 
collection system [was] not well suited for 
analyzing patterns or analyzing consis-
tencies in the handling of complaints.” 
Following completion of the OIG audit, 
numerous other bills were introduced con-
cerning the health occupation boards. In 
response to all of these bills, the DHMH 
suggested the creation of the Task Force. 
Given the numerous issues which the 
legislature listed for Task Force study, 
the Task Force focused its recommenda-
tions on four broad areas: fairness (in both 
process and outcome of board disciplinary 
actions); timeliness of board action; com-
munication between boards, respondents 
and complainants, and between boards and 
the public; and data collection on various 
aspects of board actions. 
Because HB 811 made substantial refer-
ence to due process issues, it was one of 
the most significant issues tackled by the 
Task Force. For the purpose of discipline, 
boards work within the framework of ad-
ministrative law and it was the differences 
between what due process requires in the 
administrative law context and what it 
requires in the judicial context that raised 
a significant number of concerns for some 
Task Force members. In particular, two 
features of the boards’ process raised con-
cerns about conflicts of interest: 1) board 
members may participate in some cases 
in both the investigative and adjudicatory 
phases of a single case; and 2) the OAG 
provides attorneys to both prosecute board 
cases and advise boards as board counsel. 
As background, in terms of the role 
of board members, the law in Maryland 
and most states allows board members 
to participate in investigating complaints 
and, later, in the adjudication process. In 
Dr. K. v. State Board of Physicians Quality 
Assurance,1 the Maryland Court of Special 
Appeals approved of this practice noting 
that “an investigation is not a disciplinary 
action” that triggers conflict of interest 
concerns. In terms of the dual role of the 
OAG, the United States Supreme Court 
held in Withrow v. Larkin2 that the combi-
nation of investigatory, prosecutorial, and 
adjudicatory functions in an administrative 
agency is not, in and of itself, a denial of 
procedural due process rights. Nor does 
the Administrative Procedure Act prohibit 
agency personnel engaged in prosecution 
or investigatory functions from participat-
ing in an adjudication to the extent that 
they are acting as counsel in such a pro-
ceeding. The Task Force’s recommenda-
tions in this area included the requirement 
that boards have a separate charging com-
mittee and guidelines relating to timeliness 
of charges.
Another significant Task Force recom-
mendation was a requirement that the 
boards establish sanctioning guidelines. 
HB 811 required the Task Force to study 
“[p]otential changes in the disciplinary 
program of the health occupation boards 
that will . . . (iii) increase the consistency 
and fairness of disciplinary outcomes.” 
In order to arrive at more consistent and 
fair outcomes, the Task Force studied and 
later recommended the development of 
sanctioning guidelines. Approximately 
20 states have adopted or are considering 
adopting structured sanctioning systems 
including Virginia, Ohio, Washington, 
Florida, Ohio, and Texas.3 
Sanctioning guidelines provide a 
framework from which an appropriate 
Maryland Delegate  
Shirley Nathan-Pulliam
Law & HeaLtH Care NewsLetter │ 11
sanction can be reached by a disciplinary 
board. There are several reasons for adopt-
ing sanctioning guidelines: they make 
sanctioning decisions more predictable; 
they add an objective element to a process 
that is inherently subjective; they provide 
a resource for board members, board staff 
and attorneys on both sides; they minimize 
sanctioning inconsistencies; assist board 
members or staff recall how past cases 
were decided; and constrain the influence 
of such undesirable factors as board mem-
ber identity, overall board makeup, and 
race or ethnic origin on outcomes. 
The legislation creating the Task Force 
also listed as a topic for study “the extent 
to which the current disciplinary system 
has a differential impact on various groups 
of licensees and potential strategies for 
minimizing differences while improving 
the overall quality of health care services.” 
This was in response to prior concerns 
relating to the dental board. Given the 
fact that not all boards know the racial or 
ethnic background of their licensees, it is 
difficult to determine whether board disci-
plinary actions have a differential impact 
on licensees based on race or ethnicity. 
Therefore, the Task Force recommended 
that all boards collect data relating to a 
licensee’s race and ethnicity on licensing 
applications to provide statistical infor-
mation that could later be used to verify 
fairness in licensure and disciplinary pro-
cesses and to ensure that board member-
ship reflects diversity of licensees.
The Task Force staff researched the 
legality of collecting such data and de-
termined that there is no federal or state 
statutory prohibition against collecting 
this type of information.4 Further, federal 
law allows private entities to collect racial 
and ethnic identity information for certain 
housing, lending, and banking transac-
tions. In Maryland, several state agencies 
currently ask applicants for this informa-
tion as do the majority of the boards.
Hoffmann, accompanied by Rowthorn 
and Ameringer, testified in Annapolis be-
fore the House Health and Governmental 
Operations Committee regarding the work 
of the Task Force on February 3. In the 
weeks following the hearing, bills contain-
ing the Task Force recommendations were 
introduced in both houses of the Mary-
land General Assembly (H.B. 1275 and 
S. 956). More information about the Task 
Force and the final report are available at 
http://www.dhmh.state.md.us/reports/pdf/
feb09/Other/HB0811_TF%20Discipline_
HC%20Prof.pdf.
1 98 Md. App. 103, 110 (1993).
2 421 U.S. 35 at 56 (1975).
3 Kauder, N. and Carter, E., “An Empirical-
ly Based Structured Sanctioning System,” 
Journal of Medical Licensure and Disci-
pline, Vol. 90, No. 4 (2004).
4 A helpful resource in this area was the 
2007 survey by the National Health Law 
Project (NHeLP) which found no prohibi-
tion in federal law against collection of 
racial and ethnic data when used for certain 
purposes. The NHeLP report is avail-
able at http://www.healthlaw.org/library/
item.157293-51State_Survey_of_Assess-
ment_of_State_Laws_Regulations_and_
Practices_AffectNational Health Law 
Project.
plndp.org/Resources/SBIRT_posit_paper.
pdf.
2 Health Matrix: Journal of Law-Medi-
cine, Vol. 20 (forthcoming).
3 75 UMKC L. Rev. 789 (Spring 2007).
4 SAMHSA Factsheet: National House-
hold Survey on Drug Abuse, 2001, avail-
able at http://www.whitehousedrugpolicy.
gov/drugfact/nhsda01.html.
5 Join Together: Ensure Equal Coverage 
for Treatment, available at http://www.
jointogether.org/keyissues/coverage/equal-
treatment-readmore.html. See also Town 
M, Naimi TS, Mokdad AH, Brewer RD. 
“Health care access among U.S. adults 
who drink alcohol excessively: missed op-
portunities for prevention.” Prev Chronic 
Dis [serial online] April 2006.
6 In March 2006, the New England 
Journal of Medicine published a study of 
seven Federal Employee Health Benefits 
(FEHB) plans from 1999 through 2002. 
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tal health courts, domestic violence courts, 
and others. 
10 The chapter will be included in Prob-
Lem-soLviNg Courts: JustiCe for tHe 
tweNty-first CeNtury? (P. Higgins & M. 
Mackinem eds. 2009) (in press). 
11 The Health Consequences of Smoking: 
Nicotine Addiction: Report of the Surgeon 
General (1988), Center for Health Promo-
tion and Education, Office on Smoking 
and Health, Office of the Surgeon Gen-
eral. Davis, R., et al., Editors. Available at 
http://profiles.nlm.nih.gov/NN/B/B/Z/D/.
12 National Institute on Drug Abuse, Re-
search Report Series, Tobacco Addiction, 
NIH Publication Number 06-4342. Printed 
July 1998, Reprinted August 2001, Re-
vised July 2006, available at http://www.
nida.nih.gov/PDF/RRTobacco.pdf.
13 This provision covers Wellbutrin, Zyban 
and nasal inhalers.
Study authors found no increase in total 
costs for FEHB providers when mental 
health parity was coupled with managed 
care. Employers, no matter the size, can 
save at least $2.15 for every dollar spent 
implementing alcohol SBIs (screening and 
brief interventions). Goldman, Howard H., 
et. al., “Behavioral Health Insurance Par-
ity for Federal Employees,” NEJM, Vol. 
354: 1378-1386, No. 13 (March 30, 2006).
7 In addition, all Federal employees have 
parity if they are insured through the Fed-
eral Employee Health Benefit Plan, which 
covers 9 million federal employees, their 
families, and retirees. 
8 Sec. 512 of the Emergency Economic 
Stabilization Act (H.R. 1424), P.L. 110-
343 (2008).
9 The success of drug courts has spurred 
the creation of a new generation of so 
called problem-solving or therapeutic 
courts, including community courts, men-
There are several reasons for adopting sanctioning guidelines: they make 
sanctioning decisions more predictable; they add an objective element to a 
process that is inherently subjective; they provide a resource for board mem-
bers, board staff and attorneys on both sides; they minimize sanctioning 
inconsistencies; assist board members or staff recall how past cases were 
decided; and constrain the influence of such undesirable factors as board 
member identity, overall board makeup, and race or ethnic origin on out-
comes.
Focus on L&HCP Students
Externship at the CDC by rebecca Jesada ’10
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After two years of law school and a research assistant position that introduced me to the concept of 
public health lawyering, I went in search 
of a summer position that would allow me 
to work in a setting where public health 
and the law intersect.  I was thrilled when 
I was accepted as a legal intern at the 
nation’s largest public health agency, the 
Centers for Disease Control and Preven-
tion (CDC) in their Public Health Law 
Program (PHLP) in Atlanta.  
The mission of PHLP is to improve the 
health of the public through law.  PHLP 
conducts research on the legal aspects of 
a wide range of public health issues, from 
terrorism preparedness and infectious 
diseases to obesity and lead poisoning.  
The program produces various forms of 
training and guidance for state and local 
health departments and legislators dealing 
with emerging threats, while working to 
build partnerships between policy makers, 
public health practitioners, government 
officials, and lawyers in an effort to reach 
creative solutions to public health prob-
lems.  
As a PHLP intern, the focus of my work 
was to co-author (in collaboration with a 
staff attorney) a paper for CDC’s National 
Center for Injury Prevention and Control.  
The project involved extensive research 
on state statutes and regulations concern-
ing injury prevention.  Our goal was to 
examine the relationship between states 
that mandate comprehensive injury pre-
vention programs and those that take more 
of a piecemeal approach legislatively (i.e., 
enact individual laws with much narrower 
authority in response to particular com-
munity concerns, such as a window guard 
requirement after a local child is injured).  
I also had 
the opportu-
nity to work 
on other 
projects 
throughout 
the sum-
mer.  PHLP 
is currently 
collaborat-
ing with the 
Centers for 
Law and the 
Public’s 
Health at 
Johns Hopkins and Georgetown Universi-
ties on a three-part initiative to analyze 
state tuberculosis (TB) control laws, 
develop a handbook on TB control laws 
for an audience of state, local, and tribal 
public health professionals, and develop a 
Model Act for states to use in creating or 
amending their own TB laws.  I was fortu-
nate to gain some exposure to the second 
and third phases of this effort, including 
editing the handbook and attending the 
2008 National Tuberculosis Controllers 
annual conference, during which a feed-
back session on the draft Model Act was 
held with TB controllers from around the 
country.  
Another highlight of the summer was 
the opportunity to not only attend but par-
ticipate in the 2008 National Summit on 
Legal Preparedness for Obesity Prevention 
and Control.  The summit was sponsored 
and hosted by PHLP and CDC’s National 
Center for Chronic Disease Prevention and 
Health Promotion, along with the Robert 
Wood Johnson Foundation and the Ameri-
can Society of Law, Medicine, and Ethics.  
The summit was a remarkable experience, 
which gave me the opportunity to sit down 
and share ideas with many of the schol-
ars and authors whose works I have been 
reading since college.
Reflecting on my summer at CDC, it 
was truly a unique and valuable experi-
ence that exceeded my highest expecta-
tions.  I got a strong feel for the culture 
of government work from an attorney’s 
perspective and particularly enjoyed the 
academic environment, which afforded me 
significant autonomy in pursuing the inju-
ry research.  It was inspiring to see what a 
difference health lawyers can make in the 
real world, which has fueled my eagerness 
to continue specializing in health law.
Becca, who will graduate in 2010 with 
the Health Law Certificate, is currently a 
law clerk with the University of Maryland 
Medical System Office of General Coun-
sel.  She has served as a research assistant 
for Associate Dean Diane Hoffmann and 
has a professional background in hospital 
bioterrorism preparedness, including work 
with Navy hospitals around the world and 
New York City hospitals. She is also a 
Notes & Comments Editor of the Journal 
of Health Care Law and Policy.
Rebecca Jesada
 
Tobacco Clinic Students Travel to South Africa for Conference
As students of the Tobacco Control Clinic, we had the opportunity to travel to Durban, South Africa to participate in Third Annual Conference of the Parties to the World Health Organization’s Framework Convention on Tobacco Control with Professor Chris Bostic, a Clinical Instructor in the Tobacco Control Clinic and legal counsel to the Framework Conven-
tion Alliance (FCA). The FCA is a non-governmental organization comprised of more than 350 organizations from more than 100 
countries working on the development, ratification, and implementation of the international treaty, the Framework Convention on 
Tobacco Control (FCTC). The FCTC is the world’s first global public health treaty, and requires parties to adopt a comprehensive 
range of measures designed to reduce the devastating health and economic impacts of tobacco. 
To kick off the conference, the Minister of Health invited the conference attendees to join her on a health walk through the 
streets of Durban. Chanting Vuka, South Africa, Vuka! (Move, South Africa, Move!), we joined hundreds of people marching 
together in the streets of Durban holding anti-tobacco signs. Working alongside FCA in Durban to promote the development and 
implementation of the treaty was professionally gratifying, and an eye-opening experience into the world of public health.
--Nishamarie Sherry ’10 and Jennifer Shahabuddin ’09
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Health Law Students with  
Advanced Health-Related Degrees
 
As the Law & Health Care Program 
continues to grow in national stature, 
it is attracting an increasing number of 
students who arrive at the law school 
with advanced health-related degrees 
already under their belts.  Our stu-
dent body now boasts of students with 
advanced degrees in public health, 
public policy, medicine, nursing, and 
social work, among other specialties.  
Faculty members and students alike 
deeply value the real world perspec-
tive that these students bring to the 
study of health law. Below, some of 
these students describe their academ-
ic and health care backgrounds.
Caroline Farrell (MPH ’07, JD ’10)
I graduated from The George Washing-
ton University School of Public Health 
and Health Services with an MPH with 
a concentration in health policy in 2007. 
During my time in the MPH program, I 
worked as a public policy intern at the Na-
tional Association of Community Health 
Centers where I served as an advocate for 
reauthorization of both the State Chil-
dren’s Health Insurance Program and the 
Health Centers program. At the School of 
Law, I am pursuing the health law certifi-
cate and have had the opportunity to use 
my public health training in an externship 
in the Johns Hopkins Hospital General 
Counsel’s Office, as a health policy fel-
low at the Health, Labor, Education, and 
Pension Committee in the United States 
Senate, and as an intern for the Center for 
Science in the Public Interest’s Litigation 
Project. I came to University of Maryland 
Law School to sharpen my advocacy 
skills. Long term, I hope to contribute 
to making high quality health care more 
available, accessible, and affordable for all 
Americans.
Keith Shebairo (MD ’01, JD ’10)
 I am an adult and child psychiatrist 
and a 2L day student at the law school. I 
came to the School of Law because of its 
highly ranked health law program. Before 
law school, I earned my MD degree from 
The George Washington University and 
completed a residency and fellowship in 
psychiatry. I am a licensed physician and 
board certified in adult psychiatry. Cur-
rently, I’m pursuing the health law certifi-
cate. Coming back to law school has been 
an amazing experience for me. Through 
the health law program, I enrolled this 
spring semester in the Center for Tobacco 
Regulation Clinic. Right now I am work-
ing on legislation that is being considered 
by the Maryland General Assembly. In 
addition, through opportunities at the law 
school, I interned in the United States 
Senate Subcommittee on Retirement and 
Aging this past summer. I have also been 
active with the law school’s national trial 
team. 
Lola Burford (MSW ’03, JD ’10)
A commitment to social justice requires 
dedication to advocating on behalf of 
those who are unable to do so for them-
selves. I chose to attend the School of 
Law because of the school’s commitment 
to public interest law, which is aligned 
with my career interests. I am currently a 
2L with a Masters degree in Social Work, 
from Florida Atlantic University. I have 
worked in the field of social services for 
over five years and most recently with the 
Florida Department of Health’s Children’s 
Medical Services in the Pediatric HIV/
AIDS division. Completing the Health 
Law Certificate will enable me to bet-
ter represent and advocate for vulnerable 
individuals (children, women, minorities, 
and the elderly). 
Jessica Skopac (MA ’03, 
JD/PhD ’10)
I am a 2L day student, 
pursuing the JD/PhD in Pub-
lic Policy at University of 
Maryland Baltimore County. 
I returned to the law school 
this semester after a two 
year leave of absence during 
which I conducted my dis-
sertation research on health 
policy in Croatia. Prior to 
law school, I earned an 
MA in Bioethics, also from 
UMBC. From 2000 to 2003 
I worked as the legislative 
liaison for the Maryland 
Chapter of the Academy 
of Pediatrics, representing 
the group’s interests before the Maryland 
General Assembly. Currently, I’m pursu-
ing the health law certificate and using 
my bioethics and health policy training in 
the capacity of research assistant to Dean 
Karen Rothenberg. After graduation, I 
hope to find a position as in-house council 
for a hospital/biotechnology firm/pharma-
ceutical company or work as a consultant 
for a think tank.
meg mcCoy (MPH ’07, JD ’09)
I have always been interested in issues 
that involve science, health policy, and the 
law. Before attending Maryland, I worked 
at the Institute of Medicine on two con-
gressionally-mandated reports about pedi-
atric medical devices and clinical research 
involving children. In 2007, after my 
first year in law school, I earned an MPH 
from the Johns Hopkins University. I was 
drawn to the School of Law by its health 
law program’s distinguished reputation 
and proximity to Washington, DC. As part 
of the Health Law Certificate program, I 
externed for Stephen Teret at Johns Hop-
kins’ Bloomberg School of Public Health, 
researching federal preemption of state 
statutes controlling salt content in food. 
Last summer, I worked for the Centers 
for Medicare and Medicaid Services to 
help finalize federal regulations governing 
hospital reimbursement.
Cont. on page 16
Advanced Degree Students (from l to r):, Lola Burford, 
Jessica Skopac, Meg McCoy, and Stephanie Mackowiak. 
(not pictured, Keith Shebairo and Caroline Farrell)
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riCHArD BoLDt
Publications
“Confidentiality of Alcohol and Other 
Drug Abuse Treatment Information for 
Emergency Department and Trauma 
Center Patients,” Health Matrix: Jour-
nal of Law-Medicine, Vol. 20 (forthcom-
ing). 
KAtHLeen DACHiLLe
Presentations
“Youth Access to Tobacco in Cecil 
County: A Legislative Response,” Cecil 
County Tobacco Control Task Force, 
Elkton, Maryland (September 5, 2008).
“Tobacco Legislation in the 2009 
Session of the Maryland General As-
sembly,” Maryland General Assembly 
of County Health Officers, Annapolis, 
Maryland (September 18, 2008).
“’I’m Just a Bill’”:  The Maryland Leg-
islative Process and Tobacco Control 
Legislation in Maryland,” TRASH 
(Teens Rejecting Abusive Smoking 
Habits) Annual Conference, Frederick, 
Maryland (January 11, 2008).
MD QUIT Annual Conference, Bal-
timore, Maryland:  Tobacco and the 
2009 Session of the Maryland General 
Assembly (January 22, 2009).
Publications, Writings
 “Amicus Curiae Brief in Support of 
Respondent in Altria v. Good, Supreme 
Court of the United States, No. 07-562,” 
filed on behalf of the Center for Tobacco 
Regulation and the Maryland Consumer 
Rights Coalition (June 18, 2008).
Law Synopsis:  “Pick Your Poison:  
Responses to the Marketing and Sale 
of Flavored Tobacco Products,” March 
2009 (published by the Tobacco Control 
Legal Consortium).
Media/Interviews
Quoted in “Ethics Counsel Testimony 
is Sought in Currie Probe,” Washington 
Post, Page B01, http://www.wash-
ingtonpost.com/wp-dyn/content/sto-
ry/2008/10/04/ST2008100400071.html 
(October 4, 2008).
miCHAeL greenBerger
Presentations
“Germ Warfare, Contagious Disease, 
and the Constitution,” Speaker, Stanford 
Constitutional Law Center and the Con-
stitution Project Symposium, Washing-
ton, DC (April 11, 2008).
 “Public Health and Pandemics,” Pre-
senter, 31st Annual Health Law Profes-
sor Conference, Drexel University Earle 
Mack School of Law, Philadelphia, 
Pennsylvania (June 7, 2008).
“Emergency Preparedness and the 
Special Needs Population,” Commu-
nity Action Partnership 2008 Annual 
Convention, Chicago, Illinois (August 
27, 2008).
Media/Interviews 
Panelist, “Naturally Occurring Epi-
demics and Terrorist Use of Biological 
Weapons,” C-SPAN (April 11, 2008).
Interview, “Preparation is Key to Avoid-
ing ‘Worst-Case Outcome,’ Chertoff 
Says,” The Stanford Report (April 14, 
2008).
DeBorAH HeLLmAn
Presentations
“Doctors, Decision-making and Trust 
Conflicts,” 31st Annual Health Law Pro-
fessors Conference, Drexel University 
College of Law, Philadelphia, Pennsyl-
vania (June 6, 2008).
“Willfully Blind for Good Reason,” 
University of Toronto Legal Theory 
Workshop (January 26, 2009).
 “Why Put Safety First?”presentation 
on early phase clinical research at the 
Association for Practical and Profes-
sional Ethics, Cincinnati, Ohio (March 
7, 2009).
“Willfully Blind for Good Reason,” 
University of Southern California Law 
School, Faculty Workshop (March 13, 
2009).
DiAne HoFFmAnn
Presentations
“The Disparity Toward Women in Pain: 
Social, Cultural and Legal Issues,” First 
Annual Women in Pain Conference: 
Gender Matters, City of Hope National 
Medical Center, Los Angeles, California 
(May 30, 2008).
“Is Dying a Public Health Issue?” 31st 
Annual Health Law Professors Confer-
ence, Drexel University College of Law, 
Philadelphia, Pennsylvania (June 6, 
2008).
“Health Care Reform at the National 
Level,” Election 2008: A Forum on 
Health Care Reform and the Presiden-
tial Election, University of Maryland 
Medical School, Baltimore, Maryland 
(September 30, 2008).
“Breaking the Law to Treat Patients,” at 
Richard J. Childress Memorial Confer-
ence, Still Crazy After All These Years: 
Is Regulating Physician Practice an Ex-
ercise in Futility?, Saint Louis Univer-
sity School of Law, St Louis, Missouri 
(October 17, 2008).
Facilitator, “Disparities in Pain Care,” 
Pain Summit 2008, on Future Direc-
tions in Pain Care, Baltimore, Maryland 
(sponsored by the MD/DC Pain Initia-
tive) (October 24, 2008).
“Are Ethics Committees Doing What 
We Hoped?” at Health Care Ethics 
Committees & Maryland Law – Time 
for a Change? MHECN Conference, 
Baltimore, Maryland (December 3, 
2008).
Berman Lecture, “Case Studies: Ge-
netics in the Courtroom,” The Johns 
Hopkins Bloomberg School of Public 
Health, Baltimore, Maryland (December 
8, 2008).
Greenwall Lecture, “Judging Genes: 
Implications of the Second Generation 
of Genetic Tests in the Courtroom,” 
the Johns Hopkins Bloomberg School 
of Public Health, Baltimore, Maryland 
(December 8, 2008).
Convener and Moderator:  “Compara-
tive Health Law and Policy:  What, if 
Anything, Can We Learn from Other 
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Countries?”  2009 AALS Annual Meet-
ing, San Diego, California (January 10, 
2009).
Publications
 “Treating Pain v. Reducing Drug 
Diversion and Abuse: Recalibrating the 
Balance in Our Drug Control Laws & 
Policies,” 1 St. Louis University Journal 
of Health Care Law and Policy 231 
(2008).
 “Achieving Quality and Responding 
to Consumers—The Medicare Benefi-
ciary Complaint Process: Who Should 
Respond?” (with Virginia Rowthorn), 
5 Indiana Health Law Review, 9-51 
(2008).
 “Are Health Care Conflicts all that Dif-
ferent? A Contrarian View”, 29 Hamline 
Journal of Public Law & Policy, 235-
242 (Spring 2008).
“Building Public Health Law Capac-
ity at the Local Level,” (with Virginia 
Rowthorn), 36 (Special Supp.) J. Law, 
Medicine & Ethics 6 (Fall 2008). 
Book chapter: (with Anita Tarzian), 
“The Role and Legal Status of Health 
Care Ethics Committees in the U.S.”, 
in LegaL PersPeCtives iN bioetHiCs: 
aNNaLs of bioetHiCs series, ed. Sandra 
Johnson, Pub. Rutledge (2008).
other Activities/Appointments/Awards 
Board of Directors, American Society 
of Law, Medicine & Ethics, (Jan. 2009 
–present).
Board of Governors, For Grace (an 
advocacy organization for women with 
chronic pain) (Jan. 2009–present).
Chair,  AALS Section on Law, Medicine 
& Health Care (2009).
Award, The Daily Record’s 2009 
Maryland’s Top 100 Women.
KAren rotHenBerg
Presentations
“Stem Cell Commissions: Politics, Poli-
cies and Prospects,” 31st Annual Health 
Law Professors Conference, Philadel-
phia, Pennsylvania (June 6, 2008).
“Genetics Research and Its Implications 
for the Jewish Community,” Children’s 
National Medical Center Symposium, 
Washington, DC (June 11, 2008).
“In the Family” Documentary Premier 
Panel Discussion, Participant, Silver-
docs, AFI/Discovery Channel Docu-
mentary Film Festival, Washington, DC 
(June 18, 2008).
Publications
Book chapter: “The Scarlet Gene: 
Behavioral Genetics, Criminal Law, 
and Racial and Ethnic Stigma,” (with 
Amanda Wang) Ch. 13. in tHe imPaCt 
of beHavioraL sCieNCes oN CrimiNaL 
Law, Oxford University Press, (March 
9, 2009).
Media/Interviews 
Interview, WYPR-FM, “Changing the 
Way We Look at Stem Cells” (March 9, 
2009). 
Interview, WBFF-TV, Ch. 45, “U.S. 
Stem Cell Funds Freed; Md. Debates Its 
Own” (March 9, 2009).
Interview, The Daily Record, “Effect 
of Obama’s Stem Cell Reversal Could 
Take Years” (March 9, 2009). 
Interview, The Washington Post, “U.S. 
Stem Cell Funds Freed; Md. Debates Its 
Own” (March 10, 2009).
Interview, WBAL-AM, “U.S. Stem Cell 
Funds Freed; Md. Debates Its Own” 
(March 11, 2009).
Interview, WYPR-FM, “Stem Cell 
Order Could Be Boon for Maryland” 
(March 17, 2009). 
Interview, NPR “Morning Edition,” 
“States Rethinking Costly Stem Cell 
Programs” (March 23, 2009).
other Activities/Appointments/Awards 
Co-Chair, World Stem Cell Summit 
(2009).
Chair, Maryland Stem Cell Research 
Commission (July 2008).
JACK SCHwArtz
Presentations
“Apology for Medical Error,” Eth-
ics Grand Rounds, Maryland General 
Hospital, Baltimore, Maryland (October 
30, 2008).
“Legal Framework for Advance Care 
Planning,” Geriatric Imperative Min-
imester, University of Maryland Balti-
more, (January 7, 2009).
“Making Sense of Living Wills and 
Advance Directives,” Kimmel Compre-
hensive Cancer Center, Johns Hopkins 
Hospital, Baltimore, Maryland (March 
31, 2009).
“Making Sense of Living Wills and Ad-
vance Directives,” Southern Maryland 
Caregivers’ Conference, Prince Freder-
ick, Maryland (April 17, 2009).
Publications, Writings
“Harnessing Complex Hospital Care: 
Hospital Practices Must Match the 
Moral Ends of Treatment,” (with Evan 
DeRenzo and Steven Selinger), Science 
Progress (published online by Center 
for American Progress) (January 2009).
“Content of Advance Directives for 
Individuals with Advanced Dementia,” 
(with Patrick Triplett et al.), 20 Journal 
of Aging and Health 583 (2008).
“Surrogate Decision Making: Rec-
onciling Ethical Theory and Clinical 
Practice,” (with Jeffrey Berger and 
Evan DeRenzo), 149 Annals of Internal 
Medicine 48 (2008).
eLLen weBer
Presentations
“Disability Discrimination and Health 
Privacy Standards,” University of Mary-
land School of Medicine, Addiction 
Psychiatry Fellows Forum, Baltimore, 
Maryland (December 22, 2008).
 “Reluctance of and Restrictions on 
Physician Prescribing,” Conference on 
Obstacles to the Development and Use 
of Pharmacotherapies for Addiction, 
University of Maryland School of Law 
(November 7, 2008).
“Protecting Civil and Health Privacy 
Rights of Patients: The Americans with 
Disabilities Act and Confidentiality of 
Patient Records,” Maryland Society of 
Addiction Medicine, Baltimore, Mary-
land (March 7, 2009).
Media/Interviews 
Quoted:  “City government seems 
addicted to delay,” The Daily Record, 
(January 30, 2009).
Quoted:  “Rawlings-Blake withdraws 
support for group home measure: City 
Council president’s decision could trig-
ger federal lawsuit,” The Baltimore Sun 
(March 16, 2009). 
Interviewed:  “Zoning bias:  Our view: 
Court fight over group homes law would 
delay needed zoning changes; instead, 
City Council should show leadership, 
Cont. on page 16
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Comments and letters should be 
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Stephanie mackowiak (BSN ’05, JD ’10)
After receiving my undergraduate 
degree from the University of Richmond, 
I attended the University of Maryland 
School of Nursing and graduated with a 
BSN in 2005. I then worked as a critical 
care nurse for the Johns Hopkins Hospi-
tal for several years before deciding on 
a career in law. The School of Law has 
provided me with the unique opportunity 
to combine my nursing and legal experi-
ences through the Health Law Certificate 
program. Since arriving at the law school I 
have been able to use my nursing back-
ground in an externship with the Legal 
Department of the Johns Hopkins Health 
System. This summer I will be working 
with MedStar Health and hope to secure a 
position in a health law related field in the 
coming year.
work toward a compromise,” The Balti-
more Sun (March 18, 2009).
other Activities/Appointments/Awards 
2009 Public Citizen Award, National 
Association of Social Workers– 
Maryland (March 2009).
DeBorAH weimer
Presentations
Panelist, “Medical-Legal Partnerships in 
the Law School Setting,” at 2009 AALS 
Annual Meeting (January 9, 2009).
Speaker, “Current Issues Facing Women 
Living with HIV,” UMB interdisciplin-
ary conference for law, medicine, social 
work nursing and pharmacy students 
(January 11, 2009).
L&HCP Faculty Notes 
Cont. from p. 15
Non-Profit Org.
U.S. Postage
PAiD
Baltimore, MD
Permit No. 2439
